Phase 2
Completed N=153
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Heart Failure, Diastolic
Source: ClinicalTrials.gov NCT03133793 ↗
Enrolled (actual)
153
Serious AEs
21.6%
Results posted
Mar 2022
Primary outcomePrimary: Change in Health Status of Patients With HFpEF — 4.15; 26.56; 29.97; 33 Scores on a scale
Summary
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Health Status of Patients With HFpEF |
4.15; 26.56; 29.97; 33 | — |
| SECONDARY Change in Vigor |
-0.54; 7.11; 7.3; 7.61 | — |
| SECONDARY Change in Ejection Fraction (EF) |
-2.39; 4.69; 5.64; 5.07 | — |
| SECONDARY Change in Septal E/e' |
1.39; -1.27; -0.65; -0.47 | — |
| SECONDARY Change in 6 Minute Walk Test (6MWT) |
19.62; 21.21; 29.42; 36.21 | — |
| SECONDARY Change in Venous Blood B-type Natriuretic Peptide (BNP) Levels |
-18.43; -29.56; -42.94; 29.08 | — |
| SECONDARY Change in Lactate |
0.33; 0; -0.35; -0.24 | — |
| SECONDARY Change in Adenosine Triphosphate (ATP) |
-189.08; 1133.5; 907.44; 686.19 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed with HFpEF within a 6-month period
- New York Heart Association (NYHA) Classification II-III HF
- Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram
- Have a telephone or reliable phone contact
- Have their own means of transportation to the study site
Exclusion Criteria
- Acute coronary syndrome in the past 12 weeks
- Significant valvular heart disease
- Severe cardiac fibrosis (galectin-3 level > 26 ng/ml)
- Constrictive pericardium
- Pulmonary fibrosis
- Congenital heart disease
- Hypertrophic or infiltrative cardiomyopathy
- Heart transplant
- Left ventricular assist device
- Heart failure (HF) associated hospital admission or emergency room visit within past 30 days
- Recent percutaneous coronary intervention
- Significant renal and/or hepatic dysfunction
- Severe cognitive impairment
- Consumption of any CoQ10 (ubiquinol) or D-ribose supplements
Data sourced from ClinicalTrials.gov (NCT03133793). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.